



FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: BRISIO INNOVATIONS INC. (the "Issuer").

Trading Symbol: BZI

Number of Outstanding Listed Securities: 41,517,368

Date: April 5, 2018

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Brisio Innovations Inc. ("Brisio" or the "Issuer") is focused on the acquisition, development and marketing of software applications for mobile computing devices, including smartphones, tablets, and wearable computers.

Throughout the month of March, the Issuer remained in contact with management of Vigil Health Solutions Inc. ("Vigil"), Lite Access Technologies Inc. ("Lite Access"), ImmunoPrecise Antibodies Ltd. ("ImmunoPrecise"), and Pioneering Technologies Corp. ("Pioneering").

On March 7, 2018, the Issuer announced that it had signed a definitive share purchase agreement (the "Definitive Agreement") with NameSilo, LLC ("NameSilo") whereby the Company has agreed to acquire all of the issued and outstanding securities of NameSilo (the "Transaction"). With a priority of no interruption to existing customers or NameSilo's growth trajectory, the Transaction will not impact the existing operations of NameSilo and the founders, who are also the owner/operators of NameSilo and who will continue in their current roles and continue operating the business. Further, there are no planned changes to the system infrastructure or operational policies of the business. NameSilo is a low-cost provider of domain name registration and management services, and is an ICANN-accredited registrar. NameSilo is a high growth

registrar with nearly 1.5 million domains under management, and over 85,000 customers from approximately 160 countries. According to RegistrarOwl.com, which provides domain registrar industry statistics from ICANN, NameSilo is the 6th-fastest growing registrar in the world based on percentage growth of new registrations, and 6th-fastest growing registrar in the world when based on net new registrations, behind household names such as Google, GoDaddy and Alibaba.

On March 27, 2018 the Issuer announced that it intends to complete a non-brokered private placement financing (the "Financing") of a minimum of 18,571,428 shares (each, a "Share") at a price of \$0.35 per Share for gross proceeds of a minimum of \$6,500,000 (the "Financing"). The Company may pay finders a fee in cash and/or share purchase warrants in connection with the Financing. The proceeds of the Financing will be used for the Company's acquisition of NameSilo LLC and working capital purposes.

2. Provide a general overview and discussion of the activities of management.

Management was actively engaged in all general administrative and sundry duties of the Issuer, and focused on creating strategic relationships. The Issuer also remained in contact with management of Vigil Health Solutions Inc., ("Vigil") Lite Access Technologies Inc. ("Lite Access"), ImmunoPrecise Antibodies Ltd. ("ImmunoPrecise"), and Pioneering Technologies Corp. ("Pioneering").

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

No new products or services were developed to completion or offered in the current reporting month.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

No products or services were discontinued in the reporting month.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Aside from the disclosure in point 1 hereinabove, there have been no new relationships entered between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. in the reporting month.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Aside from the disclosure in point 1 hereinabove, no contracts or agreements expired or were terminated between the Issuer, the Issuer's affiliates or third parties. In addition, there were no cancellations of any previously announced financing arrangements.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

The Issuer made no significant acquisitions or dispositions during the reporting month. On occasion, the Issuer will acquire or dispose of publicly traded shares of companies. These transactions are disclosed in the Issuer's quarterly financial statements.

8. Describe the acquisition of new customers or loss of customers.

The Issuer made no significant acquisitions of new customers or loss of customers.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on brand names, licenses, patents, and software during the reporting month.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no key hirings, terminations, or lay-offs during the reporting month.

11. Report on any labour disputes and resolutions of those disputes if applicable.

The Issuer was not involved in any labour disputes in the reporting month.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

During the reporting month, there were no significant legal proceedings instituted against the Issuer.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

During the reporting month, no indebtedness was incurred or repaid outside of the normal course of operations.

14. Provide details of any securities issued and options or warrants granted.

No common shares, stock options or share purchase warrants were issued by

the Issuer or exercised in the reporting month.

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons in the reporting month, although management is owed funds from time to time as a result of the accrual of salary for cash flow management purposes.

16. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members in the reporting month.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There are no trends, commitments, events or uncertainties known to management which could reasonably be expected to have a material effect on the Issuer's business, the Issuer's financial condition or results of operations.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 5, 2018.

Paul Andreola
Name of Director or Senior
Officer

(s) Paul Andreola
Signature

President, CEO and Director
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/D
BRISIO INNOVATIONS INC.	March, 2018	2018/04/05
Issuer Address #1052 – 409 Granville Street		
City/Province/Postal Code Vancouver, British Columbia V6C 1T2	Issuer Fax No. (604) 683-7589	Issuer Telephone No. (604) 644-0072
Contact Name Paul Andreola	Contact Position President, CEO and Director	Contact Telephone No. (604) 644-0072
Contact Email Address Paul@Brisio.com	Web Site Address http://www.Brisio.com/	